SAN DIEGO--(BUSINESS WIRE)--Jun. 18, 2012-- Illumina (NASDAQ:ILMN) announced today that the company has filed an additional patent infringement suit against Complete Genomics, Inc. Illumina is seeking all available remedies, including injunctive relief.
The new suit, filed in the U.S. District Court for the Southern District of California, is based on Complete Genomics’ infringement of U.S. Patent No. 8,192,930, entitled “Method for Sequencing a Polynucleotide Template.” The suit targets Complete Genomics’ Combinatorial Probe-Anchor Ligation (cPal) read technology.
Illumina previously sued Complete Genomics for infringement of U.S. Patent No. 6,306,597, in the U.S. District Court for the Northern District of California. On February 8, 2012, the Court in that case issued a Claim Construction Order providing the Court’s interpretation of the disputed patent terms which affirmed the breadth of the patent and supports Illumina’s position that Complete Genomics infringes that patent.
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina owns or has exclusive licenses to more than 250 patents granted in the U.S. and many additional patents granted worldwide.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: Illumina
Illumina, Inc.
Investors:
Kevin Williams, MD
Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-882-6822
pr@illumina.com
